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ABSTRACT

Yermakov Leonid M. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2019. Type 2 Diabetes Leads to Impairment of Cognitive Flexibility and
Disruption of Excitable Axonal Domains in the Brain.

Type 2 diabetes is a metabolic disease affecting millions of people around the world.
Cognitive and mood impairments are among its many debilitating complications, but
disease mechanism(s) remain elusive. Here, we present a series of behavioral tasks that
demonstrate impairment of cognitive flexibility in db/db mice, a commonly used type 2
diabetes model. Using immunohistochemistry, we demonstrate disruption of axon initial
segments (AIS) and nodes of Ranvier, excitable axonal domains regulating neuronal
output, in brain regions associated with cognitive and mood impairments. Finally, we
present results of exercise treatment that ameliorates AIS disruption in these animals.
Establishing cognitive flexibility deficits in db/db mice that parallel disease
complications in patients with type 2 diabetes allows future research to test novel
treatment strategies, while discovering disruption of excitable axonal domains fills the
missing gap in our understanding of disease pathophysiology.
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PURPOSE AND AIMS
Purpose
Type 2 diabetes prevalence worldwide is growing at an alarming rate. There is an
established risk of dementia and depression in patients with type 2 diabetes, as well as a
growing awareness of subtle structural and functional cerebral changes that precede
development of major neuropsychiatric deficits. One of the key challenges is elucidation
of mechanisms behind these brain changes that would allow for creation of diseasemodifying treatments and prevention strategies.
The purpose of this research work is two-fold. First, we investigate if leptin-receptor
deficient db/db mice are suitable for studying impairment of executive functioning, a
cognitive domain commonly affected in patients with type 2 diabetes. Second, we
examine excitable axonal domains in the brain regions linked to cognitive and mood
impairments in type 2 diabetes. Together, these findings will further our understanding of
diabetes-associated cognitive dysfunction and provide a model for testing future
treatment avenues.
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Specific Aims
Specific Aim 1.
Hypothesis: Executive functioning is impaired in type 2 diabetic db/db mice.

Impairment of executive functioning is a major peril for patients with type 2 diabetes,
reducing quality of life and ability for diabetes management. Despite the significance of
this impairment, the status of executive functions has been largely overlooked in diabetic
animal models. Using a battery of behavioral tasks, we evaluate executive functioning in
db/db mice, a model of type 2 diabetes, during early and prolonged disease stages. We
expect to identify impairment in one or more of the executive functions, making db/db
mice suitable for future testing of this important cognitive domain.
Specific Aim 2.
Hypothesis: Excitable axonal domains are disrupted in brain regions linked to cognitive
and mood impairment in type 2 diabetic db/db mice.

Disruption of excitable axonal domains has been identified in several central nervous
system diseases, such as multiple sclerosis, schizophrenia and stroke. The implication for
this disruption is disturbed neuronal network activity, which, in turn, produces cognitive
and mood deficits observed in these diseases. Using immunohistochemistry, we examine
excitable axonal domains in the brain regions linked to cognitive and mood impairment
in db/db mice during early and prolonged disease stages. We expect to identify disruption
in the excitable axonal domains in db/db mice, providing a novel target for diseasemodifying treatments and prevention strategies.
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Specific Aim 3.
Hypothesis: Exercise treatment reduces Axon Initial Segment shortening in type 2
diabetic db/db mice.

We observed significant shortening of axon initial segment (AIS), one of the excitable
axonal domains, in db/db mice starting as early as 10 weeks of age. To determine if AIS
shortening was caused by type 2 diabetes, we implement exercise treatment in prediabetic 5-week-old db/db mice and evaluate AIS length at 10 weeks of age. We expect
that glycemic control via exercise significantly reduces the degree of AIS shortening.
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BACKGROUND
Type 2 Diabetes and Cognitive Impairment

Cognitive and mood impairments are becoming more frequently recognized as major
neuropsychiatric deficits that interfere with daily lives of patients with type 2 diabetes
(Wrighten et al., 2009; Thabit et al., 2012; Stoeckel et al., 2016; van Sloten and Schram,
2018).
The risk of dementia is more than doubled in older patients with type 2 diabetes (Stoeckel
et al., 2016), but even without dementia, patients with type 2 diabetes experience subtle
cognitive deficits across all ages (Biessels et al., 2014). Among cognitive impairments
observed in patients with type 2 diabetes are impaired long-term memory (Gold et al.,
2007; Palta et al., 2014), cognitive flexibility (Thabit et al., 2012; Sadanand et al., 2016),
and working memory (Chen et al., 2014b). Neuroanatomical abnormalities in the
prefrontal cortex (Kumar et al., 2008) and hippocampus (Gold et al., 2007)—key brain
regions associated with cognition and mood—have been observed using MRI of patients
with type 2 diabetes. In addition to its negative impact on quality of life, diabetes-related
cognitive dysfunction can exacerbate the course of the disease, since treatment relies
heavily on self-care capacity (Feil et al., 2012). In particular, cognitive flexibility and
working memory are two executive functions essential for successful management of the
disease (Black et al., 2018).
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Excitable Axonal Domains

Synaptic inputs into neurons are integrated and converge on an output signal that is
transmitted along axons toward the targets. In myelinated axons, action potentials are
generated at the axon initial segments (AIS) (Bender and Trussell, 2012; Kole and Stuart,
2012), then regenerated at the nodes of Ranvier (Franssen and Straver, 2013) allowing a
rapid and efficient relay of information (Figure I). Together the AIS and the nodes of
Ranvier are called the excitable axonal domains.
Axon initial segment
Excitable axonal domains share nearly identical molecular organization—including ion
channels, cytoskeletal and scaffolding proteins (Figure II). The axon initial segment
(AIS) is a 20-60 µm long neuronal domain traditionally viewed to be situated between
the soma and the axon proper (Huang and Rasband, 2018). The formation of the AIS is
orchestrated by submembranous scaffolding protein ankyrinG (Figure IIB, (Griggs et al.,
2017; Nelson and Jenkins, 2017)). AnkyrinG has multiple binding partners that include
the cytoskeletal proteins βIV spectrin and αII spectrin, cell adhesion molecule NF186,
and voltage-gated ion channels, including sodium (Nav), potassium (Kv), and calcium
(Cav) (Pan et al., 2006; Susuki et al., 2016; Huang et al., 2017; Nelson and Jenkins,
2017). These ion channels regulate membrane properties of the AIS to ensure efficient
generation of action potentials.
Emerging evidence indicates that activity-dependent functional plasticity of AIS plays a
key role in maintaining neural circuit activity (reviewed in (Yamada and Kuba, 2016;
Jamann et al., 2018)). For example, deprivation of auditory input to avian brainstem
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auditory neurons caused AIS elongation, which was associated with increased neuronal
excitability, presumably as an adaptive response to compensate for the loss of auditory
nerve activity (Kuba et al., 2010). Similarly, AIS elongation was observed after sensory
deprivation in developing visual cortex (Gutzmann et al., 2014). This homeostatic
plasticity is proposed to be a mechanism that maintains network excitability by
modulating neuronal output in response to neuronal input changes.
AIS disruption in the central nervous system (CNS)
Recent human studies identified that disruption of the AIS is a key pathophysiological
event in various psychiatric and neurological disorders. For example, one of the most
significant genetic risk loci for schizophrenia is ANK3 (Athanasiu et al., 2010; Roussos et
al., 2012), a gene that encodes the master organizer for AIS assembly, ankyrinG (Nelson
and Jenkins, 2017). Compared to the post-mortem brains of healthy controls, ankyrinG
signal intensity is decreased at the AIS of pyramidal neurons in the superficial cortical
layer of schizophrenic patients (Cruz et al., 2009). In addition, the number of AIS is
dramatically reduced in surviving cortical tissue adjacent to microinfarcts in humans
(Coban et al., 2017). Structural alterations such as decreased AIS length or AIS loss are
also reported in animal models of various brain diseases, such as stroke (Schafer et al.,
2009; Hinman et al., 2013), mild traumatic brain injury (Baalman et al., 2013; Greer et
al., 2013; Vascak et al., 2017), Alzheimer’s disease (Marin et al., 2016), and multiple
sclerosis (Hamada and Kole, 2015; Clark et al., 2016a). Thus, structural changes in the
AIS are emerging as a new target of axonal plasticity and/or pathology common in a wide
variety of neurological and psychiatric disorders.
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Nodes of Ranvier
Nodes of Ranvier are 1 µm short gaps between two adjacent myelin sheaths (Figure I,
(Rasband and Peles, 2016)). Similar to AIS, nodal proteins include voltage-gated ion
channels, anchored securely to the actin cytoskeleton via the ankyrinG-βIV spectrin
complex (Figure IID). Immediately adjacent to either side of the node are the paranodes,
which are sites of attachment between the axon and myelin sheath. The primary functions
of paranodes are to facilitate saltatory conduction, prevent shunting of current, and stop
lateral diffusion of ion channels (Rosenbluth, 2009). Paranodal axoglial junctions are
formed by cell adhesion complexes consisting of the glycosylphosphatidylinositol protein
contactin (Boyle et al., 2001) and contactin-associated protein (Caspr) (Peles et al., 1997;
Bhat et al., 2001; Boyle et al., 2001). The cytoplasmic domain of Caspr interacts with
axonal adapter protein 4.1B, which in turn links it to the cytoskeletal βII and αII spectrin
complex (Figure IID) [reviewed in Susuki et al. (2016)]. Finally, juxtaparanodes are
located adjacent to paranodes and are characterized by a high density of voltage-gated
potassium channels (mostly Kv1 subtypes).
Nodes of Ranvier disruption in the central nervous system (CNS)
Nodal disruption has been reported in various CNS diseases (reviewed in (ArancibiaCarcamo and Attwell, 2014)). Like AIS, pathological perturbations at the nodes have
been linked to schizophrenia due to the critical role of ANK3 in this disease (reviewed in
(Roussos and Haroutunian, 2014)) and lacunar stroke in human patients (Hinman et al.,
2015). In a mouse model of major depressive disorder, nodal alterations in corpus
callosum were closely associated with the onset of disease (Miyata et al., 2016). Multiple
sclerosis, which is associated with early cognitive impairment (Guimarães and Sá, 2012),
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can cause early lesions that involve paranodal disruption (Coman et al., 2006; Howell et
al., 2006). Finally, paranodal disruption has been reported in ageing primates (Hinman et
al., 2006). Thus, similarly to changes in AIS, nodal structural alterations are being
explored as key pathological events in neurological and psychiatric disorders.
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Figure I. Excitable domains along myelinated axons
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Figure I. Axon initial segment (AIS) and nodes of Ranvier are the excitable axonal
domains required for neuronal output and action potential propagation.
Left panel: Mouse cortical neuron culture stained for AIS (arrow, ankyrinG in red) and
somatodendritic domain (MAP2 in blue). Scale bar = 50 µm.
Right panel: Mouse sciatic nerve section stained for node (arrowhead, ankyrinG in red)
and paranode (Caspr in green). Scale bar = 10 µm.
This panel is adapted from “Yermakov LM, Hong LA, Drouet DE, Griggs RB, Susuki K
(2019) Excitable domains along myelinated axons. Myelin – Basic and Clinical
Advances, Springer,” in press.
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Figure II. Molecular organization of excitable axonal domains
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Figure II. (A) Representative image of axon initial segment (AIS) in mouse cerebral
cortex. AIS (arrow) is labeled in green (βIV spectrin), neuronal soma in red (NeuN), and
cell nuclei in blue (Hoechst). Scale bar = 10 µm.
(B) Molecular organization of AIS. The protein complexes at AIS, including voltagegated sodium (Nav) channels, are secured by the interaction between the axonal cell
adhesion molecule NF186. An ankyrinG (AnkG)-βIV spectrin complex links Nav
channels to the actin cytoskeleton for further stabilization.
(C) Representative image of node of Ranvier immunostained for neurofascin (NF) in
blue, Caspr (paranodal axon) in green, and juxtaparanodal voltage-gated potassium
channel (Kv1.2) in red. The antibody to NF stains NF186 at nodal axolemma strongly
and NF155 at paranodal glia weakly. Arrowheads indicate node. Scale bar = 10 µm.
(D) Molecular organization of a node of Ranvier. Nodal protein complexes including
voltage-gated sodium (Nav) channels are secured by the interaction between the axonal
cell adhesion molecule NF186 and extracellular matrix protein brevican. An ankyrinG
(AnkG)-βIV spectrin complex links Nav channels to the actin cytoskeleton for further
stabilization. Paranodal axoglial junctions are formed by cell adhesion molecules, axonal
contactin and contactin-associated protein (Caspr) and glial neurofascin (NF) 155. These
junctions act as a diffusion barrier to restrict the mobility of nodal and juxtaparanodal
molecules.
This panel is adapted from “Yermakov LM, Hong LA, Drouet DE, Griggs RB, Susuki K
(2019) Excitable domains along myelinated axons. Myelin – Basic and Clinical
Advances, Springer,” in press.
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METHODS
Mice
One of the most widely used models for type 2 diabetes is the leptin receptor-deficient
db/db mice (Chen et al., 1996). Leptin is a hormone produced mostly by adipose tissue,
and circulating leptin is taken up into the brain, primarily in the arcuate nucleus of the
hypothalamus (reviewed in (Wang et al., 2014a; Fruhwürth et al., 2018)). Leptin acts on
the leptin receptor to inhibit hypothalamic neurons that express the appetite-stimulating
neuropeptide agouti-related peptide, while simultaneously stimulating nearby neurons
that express the appetite-suppressing neuropeptide proopiomelanocortin via JAK/STAT,
MAPK, and PI3K signaling pathways. Loss of leptin signaling causes severe hyperphagia
leading to obesity and manifest some type 2 diabetes-like characteristics. Indeed, db/db
mice closely mimic signs in patients with type 2 diabetes such as hyperinsulinemia,
obesity and progressive hyperglycemia (Hummel et al., 1966; Coleman and Hummel,
1974).
In this study, male and female db/db (BKS.Cg-Dock7m +/+ Leprdb/J) mice (Jackson
Laboratory, Bar Harbor, ME; RRID:IMSR_JAX:000642) aged 5-26 weeks were used.
and . Age-matched non-diabetic heterozygote littermates (db/+) were used as controls
(hereafter referred to as controls). Mice were housed in groups of three to four per cage at
22–24°C with ad libitum access to food and water within the Laboratory Animal
Resources at Wright State University under 12-h light/12-h dark conditions or in the
AAALAC International accredited vivarium at Cincinnati Children’s Research
Foundation under 14-h light/10-h dark conditions. All animal procedures were approved
by the Institutional Animal Care and Use Committee at Wright State University (Animal
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Use Protocol # 1113) or at Cincinnati Children’s Research Foundation and conform to
the United States Public Health Service Policy on Humane Care and Use of Laboratory
Animals.
Measurement of blood glucose and Hemoglobin A1c (HbA1c)
A small incision was made on the tip of the tail to obtain a drop of blood. Blood glucose
and HbA1c were measured by collecting a drop of blood onto either a TrueMetrix blood
glucose test strip (Trividia Health, Fort Lauderdale, FL) or the A1CNow+ blood
collection cartridge (PTS Diagnostics, Indianapolis, IN). Blood glucose was measured
twice from the same tail incision for better accuracy. For weekly monitored blood
glucose levels, the measurements were taken 2-3 hours after the start of the 12-hour light
cycle.
Behavioral testing

Behavioral testing was conducted at the Cincinnati Children's Research Foundation
Animal Behavioral Core. Behavioral tests with 12-15 mice per group included Morris
water maze (MWM) cued training (at 10 weeks of age), MWM spatial working memory
version (at 10 weeks), radial water maze (at 11 weeks), MWM acquisition (at 12 weeks),
MWM reversal (at 13 weeks), and open-field (at 15 weeks). MWM acquisition was
repeated at 24 weeks, followed by MWM reversal at 25 weeks of age. MWM acquisition
and reversal were followed by cued-random testing at 13 and 25 weeks of age. Mice
could not be tested blindly because of observable differences in body weight; however,
only radial water maze was scored manually. Open-field activity was quantified using an
automated photobeam system and MWM cued training, spatial working memory,
14

acquisition, reversal and cued-random outcomes were scored by automated visual
tracking software.
Open-field locomotor activity
Mice were tested for locomotor activity in photocell-based automated polycarbonate test
chambers (40 cm x 40 cm x 30 cm, PAS system, San Diego Instruments, San Diego,
CA). Mouse activity (total number of infrared beam interruptions) and ambulation
(successive beam breaks) is reported in 5 min intervals during a 1 h test period.
Morris water maze (MWM)
The test was performed as described (Vorhees and Williams, 2006) with modifications. A
white 150 cm diameter polyethylene tank filled halfway with room temperature water
(21°C ± 1°C) was used. A white platform was submerged 1.5 cm below the surface of the
water, and the size of the platform varied depending on the test phase. Except for cued
training and cued-random (during which a proximal cue was placed on the platform),
curtains around the pool were opened so that distal cues (geometric shapes and posters on
the walls) were visible. Mice were tested in rotation with the inter-trial interval
determined by the number of mice being tested at any given time; however, the time was
approximately 10 min. Latency and path efficiency (straight-line distance from start to
platform ÷ the path taken by the mouse) to reach the goal, along with mean swim speed
were measured using Any-Maze video tracking software (Stoelting Instruments, Wood
Dale, IL).
MWM cued training
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Cued training was given first to acclimate mice to the test requirements and assess
swimming ability. Curtains were closed around the pool to obscure distal cues. The
escape platform was 10 cm in diameter and contained an orange ball mounted on a steel
rod 7 cm above the water to provide a proximal cue to the platform’s location. Mice were
given six trials with fixed start and platform positions; latency to reach the goal was
recorded.
MWM spatial working memory
To assess working memory, two trials per day were administered for 6 days. The location
of a submerged 10 cm platform changed every day but did not change between trials,
making the task a trial-dependent test of working memory. The first trial on each day was
in a new location and represented the sample trial, during which the mouse learned the
location of the platform by trial-and-error. The second, test trial, assessed the recollection
of the platform location from the sample trial. Improvement of latency or path efficiency
between trials 1 and 2 reflects working memory.
MWM acquisition
To assess spatial learning, the submerged platform acquisition phase spanned 5 days with
4 trials per day and a 60 s trial limit. Four quasi-random start positions were used. The
submerged platform was 10 cm in diameter and remained in the same location during the
5 days of acquisition.
MWM reversal
To assess cognitive flexibility (i.e., the ability to extinguish the learned platform location
used in acquisition and acquire a new location), the submerged platform was moved to
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the opposite quadrant from acquisition. A 7 cm diameter platform was used to increase
task difficulty; the procedure was the same as acquisition, i.e., 4 trials/day for 5 days, but
with different start positions.
MWM cued-random
To assess proximal cue learning, mice were tested in the MWM cued-random procedure.
The 10 cm submerged platform was used but it was marked as during cued training with
an orange ball mounted on a steel rod that extended 7 cm above the water. Curtains were
closed around the pool to obscure distal cues. Whereas during cued training the start and
platform were in a fixed location, for cued-random both the start and platform were
moved on every trial such that no spatial strategy would be effective. Mice were given 4
trials per day for 2 days and latency to reach the platform was recorded.

Radial water maze (RWM)
To assess working memory, mice were tested using an 8-arm RWM (Hyde et al., 1998).
A black 210 cm diameter polyethylene tank was filled halfway with room temperature
water (21°C ± 1°C). There was a black 60 cm diameter polyethylene octagon in the center
requiring mice to choose an arm by swimming around the octagon. Posters were mounted
around the room as distal cues. Each of the maze’s 8 arms was 55 cm long and 17 cm
wide. At the start of each day, all arms had submerged platforms at the end except for the
start arm. Mice were given 7 trials per day for 7 days. After the mouse was placed at the
start arm, it was allowed to swim freely for 2 min. After a platform was found, the mouse
was given a 30 s rest in a dry cage, and the found platform was removed. If the mouse
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failed to find a platform it was given a 2 min rest. An entry into an arm without a
platform was counted as a working memory error. An entry into the start arm was
counted as a reference memory error. An entry was defined as head and forelegs crossing
an imaginary line at the entrance of an arm. The first day of testing in RWM was the
training day to teach mice task requirements, therefore day 1 results were not used in the
analyses.
Immunohistochemistry

Immunostaining
Mice were sacrificed by isoflurane overdose and brains were immediately removed and
fixed in ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer for 90 min,
cryoprotected overnight in 20% sucrose, blocked and placed in custom-made foil molds,
frozen in TissueTek O.C.T. (4583, Sakura Finetek, Torrance, CA, USA), and stored at 80°C. Coronal brain sections (35 μm) were cut using a cryostat (HM550, Thermo
Scientific, Waltham, MA) at 1.7 mm ± 0.15 mm (medial prefrontal cortex), 1.1 mm ±
0.20 mm (corpus callosum) and -1.64 mm ± 0.20 mm (hippocampus) relative to bregma.
Staining was performed using free floating sections with gentle rocking. Sections were
blocked for 1 h in 0.1 M phosphate buffer (pH 7.4) containing 0.3% Triton X-100 and
10% goat serum (PBTGS), then incubated overnight at 4°C with primary antibodies
diluted in PBTGS. Samples were washed 3 times for 10 min in PBTGS, followed by
incubation in the dark with fluorescently labeled secondary antibodies for 1 h at room
temperature. To detect cell nuclei, sections were counterstained with Hoechst 33342
(Cat# H3570, Thermo Fisher Scientific, IL, USA). Finally, immunolabeled sections were
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washed once in PBTGS, and twice in 0.1 M phosphate buffer containing 0.15% Triton X100, then carefully mounted onto slides using mounting medium (Cat# 71-00-16, KPL,
Gaithersburg, MD).
Antibodies
The following primary antibodies were used for immunostaining: mouse monoclonal
ankyrinG (N106/36, UC Davis/NIH NeuroMab Facility Cat# 75-146
RRID:AB_10673030), NeuN (Millipore Cat# MAB377 RRID:AB_2298772); rabbit
polyclonal Caspr (Abcam Cat# ab34151 RRID:AB_869934), βIV spectrin (M.N.
Rasband, Baylor College of Medicine; Texas; USA Cat# βIV SD RRID:AB_2315634),
Kv1.2 (Zhang et al., 2013); chicken polyclonal neurofascin (NF) (R&D Systems Cat#
AF3235 RRID:AB_10890736). Alexa Fluor (594, 488, 350) or AMCA conjugated
secondary antibodies were used (Jackson ImmunoResearch Laboratories, West Grove,
PA).
Image capture and AIS measurements
All images were captured on an Axio Observer Z1 with Apotome 2 fitted with a Axiocam
Mrm CCD camera (ZEISS, Thornwood, NY). For AIS analysis, three-dimensional zstack images were taken of the prelimbic area of the medial prefrontal cortex at layers 2-3
(2015 Allen Institute for Brain Science. Allen Brain Atlas. Available from: mouse.brainmap.org. Reference atlas, coronal atlas, image 39 of 132) and pyramidal layer of CA1 of
the hippocampus (Allen Brain Atlas, image 72 of 132). In medial prefrontal cortex, AIS
measurements were taken from the full mix of glutamatergic and γ-aminobutyric acid
(GABAergic) neurons in this region, of which about every 1 out 5 neurons is GABAergic
(Hendry et al., 1987; Sahara et al., 2012). In hippocampus, AIS length was measured in
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large neurons, most of them are presumably pyramidal cells. Z-stacks were then loaded in
Fiji software (Schindelin et al., 2012). Image black and white values of βIV spectrin
immunostaining were inverted to display black AIS on white background. AIS were
defined as βIV spectrin-labeled segments greater than 10 μm in length with clearly
identifiable start and end points. AIS start point was defined as sharply increased βIV
spectrin signal closest to the soma. AIS end point was defined as reduced βIV spectrin
signal to the point where it could no longer be discerned from the background. AIS that
had blunt ends were excluded, as this is likely an artifact of cutting through the AIS
during sectioning. The AIS length measurement was performed by carefully tracing the
shape of the AIS using segmented line tool in Fiji. The length was measured in around 20
AIS per section, and 3 sections were analyzed per mouse. Measurement of distance from
soma to AIS start point was performed as described previously (Harty et al., 2013). In
brief, the shortest possible distance between the neuronal soma, identified by NeuN
staining, and the most proximal portion of the AIS, identified by βIV spectrin staining,
was measured with the straight-line tool in Fiji. Measurement of AIS density was
performed per field of view (223.82 × 167.70 µm) in most superficial part of layers 2/3 of
the cortex (3 fields of view per animal). For node of Ranvier analysis, nodal gap or
paranodal length within the corpus callosum were measured using ZEN 2.3 software
(Zeiss). Image quantifications were performed by blinded observers.

Exercise treatment
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At 5 weeks of age, db/db mice and controls were subjected to forced wheel running using
an automated system to control running wheel speed and duration of rotation (Lafayette
Instrument, Lafayette, IN) as described previously (Somineni et al., 2014). Mice were
trained to run within the wheel over a 5d period. The initial rotation speed of the wheels
was set at 4 m/min and increased daily by 1 m/min until a speed of 8 m/min was reached
on d5 of training. Similarly, the duration of exercise increased daily from 15 minutes to 1
hour in 15-minute increments. After the last day of training (d5), mice were binned into
exercise and no exercise groups. The exercise regimen lasted for 5 weeks from 5 weeks
of age until 10-11 weeks of age. Mice in the exercise group were placed in the rotating
wheels 7 days/week for 1 h/day at 8 m/min. Exercise sessions took place 2-3 hours before
the end of the 12-hour dark cycle. Glucose and weight were monitored weekly. The last
glucose and HbA1c measurements were collected at 10 weeks of age, several days before
completion of exercise treatment and terminal collection of tissues for immunostaining
and western blotting analyses in control and db/db mice aged 10-11 weeks. Mice were
euthanized at the end of exercise treatment 5 hours after their last exercise session.

Western Blotting

Mice were sacrificed by isoflurane overdose and brains were immediately removed.
Frontal lobe and hippocampus were dissected, and flash frozen in liquid nitrogen and
stored at -80°C until processing. Brain tissues were homogenized in ice-cold RIPA buffer
(25 mM Tris HCl at pH 7.5, 150 mM NaCl, 1% Triton x100, 0.5% Deoxycholate, 0.1%
SDS, 10 mM EDTA) using a pestle (BioMasher, Takara Bio USA). Homogenates were
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centrifuged at 12,000 rpm (15,000 x g) for 10 min at 4°C in a Sorvall Legend Micro 21R
centrifuge (Thermo Scientific). After centrifugation, supernatant was collected into fresh,
ice-cold tubes and protein concentrations were measured using a Pierce BCA Protein
Assay (Thermo Scientific, Cat# 23225). Samples (10 µg protein) were denatured at 95°C
for 5 min in reducing sample buffer (Bio-Rad, Cat# 1610710 and #1610747), then run on
a 4–20% Mini-PROTEAN TGX stain-free gel (Bio-Rad, Cat# 4568096). The gel was
then transferred to nitrocellulose membrane, 0.45 µm pore size (Bio-Rad, Cat# 1620115).
Membranes were blocked with 20 mM Tris, pH 8.0 and 0.05% (v/v) Tween 20 (TBST)
containing 4% (w/v) milk for 1 h. Primary antibodies were diluted in TBST with milk at
1:1000, added to the membranes and incubated overnight at 4°C. Primary antibody was
washed and horseradish peroxidase (HRP) conjugated secondary antibodies (1:10,000)
were incubated for 1 h at room temperature. Signals generated by Pierce ECL Plus
Western Blotting Substrate (Thermo Scientific, Cat# 32132) were detected using a
ChemiDoc MP Imaging System (Bio-Rad). Quantification of the band density was
performed using ImageLab software from Bio-Rad. The densities of the bands of interest
were normalized to the relative expression of GAPDH. Total protein staining was used to
confirm appropriate protein loading and transfer. Western blotting was performed in
collaboration with Domenica Drouet (MS candidate).
Antibodies
The following primary antibodies were used for western blotting: mouse monoclonal
NeuN (Millipore Cat# MAB377 RRID:AB_2298772), myelin basic protein (MBP)
(BioLegend Cat# 808401, RRID:AB_2564741), GAPDH (Enzo Life Sciences Cat# ADICSA-335-E, RRID:AB_2039148); rabbit polyclonal βIV spectrin (M.N. Rasband, Baylor
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College of Medicine; Texas; USA Cat# βIV SD RRID:AB_2315634), cleaved caspase 3
(Cell Signaling Technology Cat# 9661, RRID:AB_2341188). Peroxidase conjugated antimouse, -rabbit, or -chicken secondary antibodies were used (Jackson ImmunoResearch
Laboratories, West Grove, PA).

Statistical Analyses

Behavioral data were analyzed using mixed linear ANOVA models (SAS Proc Mixed,
SAS Institute 9.3, Cary, NC). Kenward-Roger adjusted degrees of freedom were used for
these models. Diabetes was the between-subject factor and interval or day were the
repeated measure factors. Significant diabetes-related interactions were further analyzed
using slice-effect ANOVAs. Data are presented as least square (LS) mean ± standard
error of the mean (SEM). AIS and nodal data were analyzed using homoscedastic
unpaired t-tests (2-tailed) when comparing the means between two groups or using a twoway ANOVA followed by Tukey’s multiple comparisons tests for multiple groups. An
alpha value of α=0.05 was used to determine statistical significance. Correlation between
AIS length and levels of blood glucose or HbA1c were analyzed by calculating the
Pearson’s correlation coefficient. All data were analyzed using Prism 7.0 (GraphPad, La
Jolla, CA) and presented as scatter plots with mean ± SEM. Data within Results text is
reported as mean ± SEM unless otherwise noted.
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SPECIFIC AIM 1 – EXECUTIVE FUNCTIONING IN DB/DB MICE

The overall objective of this aim is to establish db/db mice as a suitable animal model for
testing diabetes-induced impairment of executive functions.

The results described in this chapter are published as “Yermakov LM, Griggs RB, Drouet
DE, Sugimoto C, Williams MT, Vorhees CV, Susuki K (2019) Impairment of cognitive
flexibility in type 2 diabetic db/db mice. Behav Brain Res.
doi:10.1016/J.BBR.2019.111978.”

Introduction
Intact executive functioning, which includes cognitive flexibility, inhibitory control,
working memory, and other abilities (Miyake et al., 2000), is key for successful
management of type 2 diabetes. Patients with type 2 diabetes need to keep track of calorie
consumption, which requires working memory, and monitor blood glucose levels while
performing other tasks, which tasks cognitive flexibility (Black et al., 2018). Therefore,
impaired executive functioning in patients with type 2 diabetes (Thabit et al., 2012;
Sadanand et al., 2016) could result in poor diabetes management, which could, in turn,
exacerbate the impairment of executive functioning (Black et al., 2018) in a vicious
positive feedback cycle.
To study type 2 diabetes and its neurocognitive complications, rodent models such as
db/db mice (Hummel et al., 1966), Zucker Diabetic Fatty (ZDF) rats (Peterson et al.,
1990), and rodents given a high-fat diet (Buettner et al., 2006) are commonly used.
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Despite the significant impact of impaired executive functioning on patients’ life and
diabetes management, most studies in diabetic animals focus on the cognitive domain of
learning and memory. Spatial learning and memory is commonly assessed using the
Morris water maze (MWM) (Li et al., 2002; Gu et al., 2017) and non-spatial memory
using novel object recognition (Stranahan et al., 2008; Fu et al., 2017). There are few
studies in type 2 diabetic animals assessing cognitive flexibility and working memory,
key processes of executive functioning. The few studies that do assess executive
functioning raise concerns of confounding effect of severe hypolocomotion of db/db mice
in land-based tasks, such as the Y-maze (Sharma et al., 2010).
We hypothesized that executive functioning is impaired in type 2 diabetic db/db mice.
Indeed, here we report significant impairment of cognitive flexibility in 10-week-old
db/db mice. Impairment in cognitive flexibility tended to worsen with prolonged disease
burden at 26 weeks of age in db/db mice. We utilize a battery of specialized water-based
tasks, such as the radial water maze and the MWM reversal phase to circumvent the
hypolocomotion issue observed in land-based tasks. We establish db/db mice as a
suitable model that parallels impairment in executive functioning observed in patients
with type 2 diabetes. This model can be used in the future to develop novel drug therapies
and further elucidate the mechanisms of cognitive impairment in type 2 diabetes.
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Results
Decreased locomotor activity in db/db mice
Previous studies showed significantly decreased locomotor activity of db/db mice starting
by 10 weeks of age (Stranahan et al., 2009; Sharma et al., 2010, 2012; Ramos-Rodriguez
et al., 2013; Guo and Lu, 2014) In our study, the open-field in 15-week-old mice showed
a main effect of diabetes on activity (F(1, 23.5) = 49.23, p < 0.0001) and a significant
diabetes x interval interaction (F(11, 199) = 3.18, p = 0.0005; Figure 1.1). Similarly, there
was a main effect of diabetes on ambulation (F(1, 23.3) = 47.65, p < 0.0001) and a
significant diabetes x interval interaction (F(11, 205) = 3.19, p < 0.0005; not shown). These
data support the idea raised by a previous study (Sharma et al., 2010) that decreased
locomotor activity of db/db mice could affect the interpretation of land-based tasks such
as Y-maze. In contrast, water-based tasks are known to minimize differences secondary
to learning, such as locomotor activity or body mass(Vorhees and Williams, 2006).
Therefore, to circumvent the problem of hypolocomotion in db/db mice, we used waterbased tasks to assess executive functions.
MWM cued training
To teach mice to escape and assess swimming ability, MWM cued training was
performed first. The db/db mice (37.3 ± 2.3 s, n = 15) took longer to locate the platform
than the lean controls (26.0 ± 2.6 s, n = 12) (F(1, 48.2) = 10.77, p = 0.0019). All mice
improved over the 6 trials (F(5, 90.1) = 10.77, p = 0.0001), although there was no
interaction with diabetes. The increased latency to locate the platform in db/db mice
compared with lean controls was likely due to their reduced swim speed (see Figures
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1.2B, 1.4B,E). Therefore, to draw conclusions in the following MWM tests, we relied on
the swim path efficiency, which is dimensionless (Vorhees and Williams, 2006).
Working memory assessment with MWM and RWM
Using spatial working memory version of the MWM similar to a previously reported
method (Cui et al., 2011), we assessed working memory in db/db mice known to have
diabetes (Hummel et al., 1966). We found a main effect of diabetes on latency during
Trial 1 (F(1, 29.8) = 11.89, p = 0.0017) and Trial 2 (F(1, 30.1) = 20.70, p < 0.0001; Figure
1.2A) and a main effect of diabetes on swim speed during the same trials (Trial 1: F(1, 23.6)
= 107.02, p < 0.0001; Trial 2: F(1, 25.5) = 42.11, p < 0.0001; Figure 1.2B). By contrast,
path efficiency was not influenced by diabetes on Trials 1 or 2 (Figure 1.2C); no
performance improvement was observed between trials. Similarly, RWM did not show a
main effect of diabetes (Figure 1.3A) or diabetes x day interaction for working memory
errors. There was also no main effect of diabetes on start arm reference errors (Figure
1.3B), but there was a diabetes x day interaction (F(5, 81.8) = 2.56, p = 0.0335), with db/db
mice making significantly more start arm reference memory errors on day 7 compared
with lean controls (Figure 1.3C). There was no main effect of diabetes (Figure 1.3D) and
no diabetes x day interaction for total errors.
MWM spatial learning and flexibility at 12-14 weeks of age
To assess spatial learning in db/db mice, MWM acquisition was used (Figures 1.4A-C).
We found a significant main effect of diabetes on latency during acquisition (F(1, 25.1) =
30.64, p < 0.0001), with no diabetes x day interaction (Figure 1.4A). We also found a
main effect of diabetes on swim speed (F(1, 25) = 200.25, p < 0.0001), but no diabetes x
day interaction (Figure 1.4B). The db/db mice took longer to reach the platform and
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swam slower than the control mice. There were no main effects of diabetes or diabetes x
day interaction on path efficiency during acquisition (Figure 1.4C). To assess cognitive
flexibility, we tested the mice on MWM reversal (Figures 1.4D-F). There was a main
effect of diabetes on latency (F(1, 27.6) = 46.73, p < 0.0001) and a significant diabetes x
day interaction (F(4, 77.8) = 2.68, p < 0.0001; Figure 1.4D), with db/db mice taking longer
to locate the platform than controls on all days. There was a main effect of diabetes on
swim speed (F(1, 25.1) = 185.91, p < 0.0001) with the db/db mice swimming slower than
controls, but no diabetes x day interaction (Figure 1.4E). There was a main effect of
diabetes (F(1, 26) = 7.39, p = 0.0115) and diabetes x day interaction (F(4, 82.4) = 2.98, p =
0.0236; Figure 1.4F) for path efficiency. The db/db mice were less efficient than the lean
controls on days 4 and 5 of reversal. At the end of reversal in 14-week-old mice, cuedrandom testing was performed. There was a significant diabetes effect on latency (F(1, 25)
= 12.25, p = 0.0018; not shown) with db/db mice taking longer to reach the cued platform
than lean controls.
MWM spatial learning and flexibility at 24-26 weeks of age
To determine the effects of prolonged type 2 diabetes on cognitive function, we re-tested
the mice in MWM at 24-26 weeks of age. In accordance with a previous study (RamosRodriguez et al., 2013; Pu et al., 2018), acquisition showed a main effect of diabetes (F(1,
25.9)

= 71.25, p < 0.0001) and a significant diabetes x day interaction on latency (F(4, 73.7) =

2.99, p = 0.0241; Figure 1.5A). Db/db mice also showed a significant effect of diabetes
on swim speed (F(1, 22.5) = 123.17, p < 0.0001), but no significant diabetes x day
interaction (Figure 1.5B). The db/db mice took longer to find the platform and swam
slower than control mice. During acquisition, unlike at the younger age (Figure 1.4C),
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there was a significant diabetes effect on path efficiency (F(1, 29.2) = 7.83, p = 0.0090) and
a diabetes x day interaction (F(4, 72.5) = 2.98, p = 0.0246). Db/db mice were less efficient
at finding the platform than controls during the first two days of acquisition (Figure
1.5C). Next, we assessed reversal in db/db mice. We found a significant effect of diabetes
(F(1, 22) = 204.9, p < 0.0001) and diabetes x day interaction on latency (F(4, 67.8) = 7.58, p <
0.0001; Figure 1.5D). Swim speed showed a main effect of diabetes (F(1, 22.2) = 212.07, p
< 0.0001) with no diabetes x day interaction (Figure 1.5E). The db/db mice took longer to
locate the platform and swam slower than control mice. Path efficiency showed a
significant main effect of diabetes (F(1, 22) = 20.43, p = 0.0002) and the diabetes x day
interaction (F(4, 88) = 5.83, p = 0.0003). There was a significant reduction in path
efficiency during days 2-5 (Figure 1.5F) compared to only days 4-5 in younger db/db
mice (Figure 1.4F). These results suggest greater impairment of cognitive flexibility in
db/db mice with advancing age, similar to what is seen in patients (Biessels et al., 2014;
Sadanand et al., 2016). At the end of reversal in 26-week-old mice, cued-random testing
was performed. There was a significant diabetes effect on latency (F(1, 22.1) = 76.41, p <
0.0001; not shown) with db/db mice taking longer to reach the cued platform than lean
controls.
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Discussion
For the first time, we report a significant impairment of cognitive flexibility in type 2
diabetic mice. This dysfunction was observed in 13-week-old db/db mice, after the
development of type 2 diabetes (Hummel et al., 1966). At 24-26 weeks of age, we found
sustained impairment of cognitive flexibility. Our findings are relevant to problems with
cognitive flexibility found in patients.
There are a number of pitfalls to assessing cognitive function in diabetic rodents. For
example, the attention set-shifting task is used to evaluate cognitive flexibility in rodents
(Shiers et al., 2018), but food restriction over 3 weeks prior to this test might affect
development of diabetes. Previous studies showed decreased locomotor activity in db/db
mice, and discussed this as a potential confounder of behavioral tasks (Sharma et al.,
2010, 2012; Ramos-Rodriguez et al., 2013; Guo and Lu, 2014), whereas another study
reported no hypolocomotion in an open-field in db/db mice (Wang et al., 2016). Limited
locomotor activity in db/db mice might be caused by factors other than obesity (RamosRodriguez et al., 2013), although the reason remains unclear. To avoid the pitfalls of food
restriction and hypolocomotion observed in db/db mice, we utilized water-based tasks,
which do not require food restriction and are relatively immune to activity or body mass
differences (Vorhees and Williams, 2006). In the MWM, the most commonly reported
measure of performance is latency to reach the goal, which could be affected by swim
speed. Swim speeds are significantly reduced in db/db mice at 10-13 (Figures 1.2B,
1.4B,E), 18 (Zhao et al., 2011), and 24-25 weeks (Figures 1.5B,E) (Infante-Garcia et al.,
2017). Although the reason for slower swimming in db/db mice is not known, multiple
factors such as diabetic polyneuropathy might be involved. Thus, the MWM latency in
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db/db mice may not accurately reflect cognitive function. To avoid this problem, we
report path efficiency (Figures 1.2C, 1.4C,F and 1.5C,F), a measure that is not sensitive
to changes in latency or swim speed (Vorhees and Williams, 2006).
Previous studies and our current results from MWM acquisition show conflicting results
of spatial memory deficits in rodent models of type 2 diabetes. ZDF rats did not show
spatial learning or memory deficits after 5 or 8 weeks of untreated type 2 diabetes
(Bélanger et al., 2004). Db/db mice at 7 weeks of age showed a difference only on day-4
of MWM path length with an unadjusted t-test, whereas an overall ANOVA showed no
effects on path length (Li et al., 2002). In another study, db/db mice at 12 weeks of age
had a significantly increased latency compared to control group, although swim speed or
path were not assessed (Wang et al., 2016). In the present study, we found no difference
in path efficiency of 12-week-old db/db mice during MWM acquisition (Figure 1.4C),
suggesting that prolonged latency of the db/db mice (Figure 1.4A) is mostly due to slow
swimming speed (Figure 1.4B). Db/db mice at 14 weeks of age showed very limited
increase of latency, statistically significant only in the last day of the MWM acquisition
phase (Ramos-Rodriguez et al., 2013). Impairment of spatial learning and memory in
db/db mice might be relatively mild at 7-14 weeks of age, which could lead to the
observed variation among the studies. At 26 weeks, latency in MWM acquisition was
significantly increased along the entire phase (Ramos-Rodriguez et al., 2013) or in 2nd to
4th days (Pu et al., 2018) in db/db mice. In our study, in 24-week-old db/db mice,
reduced path efficiency in MWM acquisition was observed on days 1 and 2 (Figure
1.5C). This might be due to (i) lack of positive transfer of training in db/db mice (i.e.
control mice retained the memory of previous task, but db/db mice did not), or (ii)
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worsening of db/db mouse MWM acquisition performance with age. Although our data
do not provide conclusive evidence, both possibilities suggest that db/db mice show agedependent memory disturbance as suggested before (Ramos-Rodriguez et al., 2013). We
also did not find disturbance in working memory by MWM spatial working memory
(Figure 1.2) or RWM (Figure 1.3) in db/db mice. In contrast, impairment of cognitive
flexibility in db/db mice was clearly shown by decreased path efficiency in MWM
reversal at 13 (Figure 1.4F) and 25 weeks (Figure 1.5F).
Taken together, our findings in db/db mice as well as previous observations in patients
with type 2 diabetes suggest that executive functioning, and cognitive flexibility in
particular, is one of the impaired cognitive domains in the diabetic brain. Db/db mice
could provide a useful model to test the effects of new treatment strategies to improve
executive functioning during type 2 diabetic condition. To evaluate spatial learning and
executive functions in db/db mice without the confound of slower swim speeds, future
studies should assess path efficiency in MWM acquisition and reversal tasks.
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Figure 1.1. Decreased locomotor activity of db/db mice in open-field
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Figure 1.1. Data collected in 5 min intervals over a span of 60 min.
All values are LS Mean ± SEM. Group sizes: control = 12; db/db = 13. Mice were 15
weeks old at the time of testing. *p ≤ 0.05 vs. control.
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Figure 1.2. Db/db mice performance on Morris Water Maze spatial working memory task
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Figure 1.2. (A) Db/db mice had significantly longer latencies than lean controls in both
trials.
(B) Db/db mice had significantly slower swim speeds in both trials.
(C) There was no difference in path efficiency. All values are LS Mean ± SEM. Group
sizes: control = 12; db/db = 15. Mice were 10 weeks old at the time of testing. **p <0.01,
***p ≤ 0.001 when compared with controls.
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Figure 1.3. Db/db mice performance on Radial Water Maze task
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Figure 1.3. (A) There was no difference in the number of working memory errors
between db/db and lean controls.
(B) There was no difference in the number of start arm errors between db/db and lean
controls.
(C) Db/db mice had significantly more start arm errors on day 7, but not on days 2-6.
(D) There was no difference in the number of total errors between db/db and lean
controls. All values are LS Mean ± SEM. Mice were 11 weeks old at the time of testing.
Group sizes: control = 12; db/db = 15. **p ≤ 0.01, vs. control. ns = not significant.
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Figure 1.4. 10-week-old db/db mice performance on Morris Water Maze task
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Figure 1.4. MWM Acquisition (A-C) and Reversal (D-F).
(A) Db/db mice had significantly longer latencies to reach the platform than lean
controls.
(B) Swim speed stayed constant during acquisition.
(C) Path efficiency was similar in control and db/db mice on days 1-5 of acquisition.
(D) Db/db mice had significantly longer latencies to reach the platform than lean
controls.
(E) Swim speed stayed constant during reversal.
(F) Path efficiency was decreased in db/db mice compared to controls on days 4 and 5.
All values are LS Mean ± SEM. Group sizes: control = 12; db/db = 15. Mice were 12-13
weeks old at the time of testing. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs. control.
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Figure 1.5. 26-week-old db/db mice performance on Morris Water Maze task
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Figure 1.5. MWM Acquisition (A-C) and Reversal (D-F).
(A) Db/db mice had significantly longer latencies to reach the platform than lean
controls.
(B) Swim speed stayed constant during acquisition phase.
(C) Db/db mice were significantly less efficient than lean controls on days 1 and 2.
(D) Db/db mice had significantly longer latencies to reach the platform than lean
controls.
(E) Swim speed stayed constant during reversal phase.
(F) Path efficiency was decreased in db/db mice compared to lean controls on days 2-5.
All values are LS Mean ± SEM. Group sizes: control = 9 (3 controls excluded due to
injuries from fighting); db/db = 15. Mice were 24-25 weeks old at the time of testing. **p
≤ 0.01, ***p ≤ 0.001 vs. control.
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SPECIFIC AIM 2 – EXCITABLE AXONAL DOMAINS IN DB/DB MICE

The overall objective of this aim is to analyze excitable axonal domains in brain regions
associated with cognitive and mood impairment in db/db mice.

The results described in this chapter are published as “Yermakov LM, Drouet DE, Griggs
RB, Elased KM, Susuki K (2018) Type 2 diabetes leads to axon initial segment
shortening in db/db mice. Front Cell Neurosci 12:146. doi:10.3389/fncel.2018.00146”
and “Yermakov LM, Griggs RB, Drouet DE, Sugimoto C, Williams MT, Vorhees CV,
Susuki K (2019) Impairment of cognitive flexibility in type 2 diabetic db/db mice. Behav
Brain Res. doi:10.1016/J.BBR.2019.111978.”

Introduction
Type 2 diabetes is associated with increased risk of developing mild cognitive
impairment, mood disorders and dementia, and interferes with the daily life of patients
(Stoeckel et al., 2016). Studies in patients with type 2 diabetes indicate functional and
neuroanatomical abnormalities in prefrontal gray matter (Kumar et al., 2008) and
hippocampus (Gold et al., 2007). Detailed mechanism of how diabetes leads to these and
other neurological complications is not fully understood. Previous studies investigating
diabetic brain complications focused mainly on neuronal loss (Ramos-Rodriguez et al.,
2013; Wang et al., 2016; Infante-Garcia et al., 2017) or altered neuronal input in the form
of synaptic plasticity (Li et al., 2002; Stranahan et al., 2008) although normal brain
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function relies on both neuronal input and output signals. The impact of type 2 diabetes
on neuronal output remains a critical gap in knowledge.
The key structures for neuronal output are the excitable axonal domains: the axon initial
segments (AIS) and the nodes of Ranvier. Synaptic inputs into the neuron are integrated
and converge on the initiation of action potentials at the AIS that are propagated along
myelinated axons via the nodes of Ranvier (Bender and Trussell, 2012; Kole and Stuart,
2012). Thus, excitable axonal domains contribute to transmitting information and
enabling network communication between neurons. Importantly, changes in AIS
structures (length and/or location), as detected by ankyrinG or βIV spectrin
immunofluorescence, alter excitability and firing behavior of neurons (reviewed in
(Yamada and Kuba, 2016; Jamann et al., 2018)). Similarly, structural alterations at the
nodes or the flanking paranodes, as detected by neurofascin 186 and Caspr
immunofluorescence, can influence conduction velocity along the axons (Babbs and Shi,
2013).
We hypothesized that excitable axonal domains are disrupted in the brain regions
associated with cognitive and mood impairment in type 2 diabetic db/db mice. Indeed,
here we report AIS shortening in both prefrontal cortex and hippocampus in 10-week-old
db/db mice and additional disruption of nodes of Ranvier along the corpus callosum at 26
weeks of age. These results provide new insights into pathophysiology of
neuropsychiatric complications in type 2 diabetes.
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Results
AIS length is reduced in db/db mouse prefrontal cortex
To test the hypothesis that type 2 diabetes leads to structural alteration of the AIS, we
first analyzed the brains of female db/db mice at 10 weeks of age. These db/db mice had
profoundly elevated blood glucose levels (529.8 ± 32.3 mg/dL, n=3 mice) compared to
controls (138.5 ± 2.5 mg/dL, n=3 mice) [p=0.0003, unpaired t-test], as previously
reported (Hummel et al., 1966). To visualize AIS structures, we immunostained coronal
brain sections with antibodies to the AIS proteins ankyrinG or βIV spectrin. In medial
prefrontal cortex of both control and db/db mice, overall structures of neurons and AIS
were mostly preserved (Figure 2.1A,B). However, the length of the AIS was significantly
decreased in db/db (24.52 ± 0.48 µm, n=3 mice) compared to control (26.65 ± 0.35 µm,
n=3 mice) mice [p=0.0232, unpaired t-test] (Figure 2.1C). The cumulative frequency plot
of individual AIS lengths in db/db mice showed a leftward shift and a distribution similar
to control mice (Figure 2.1D). We also checked for altered location of the start of the AIS
relative to the soma, as both proximal and distal shifts of the AIS are recognized as
mechanisms of axonal functional plasticity (reviewed in (Yamada and Kuba, 2016;
Jamann et al., 2018)). There was no difference in distance from soma to AIS start point
between control (1.245 ± 0.0207 µm, n=3 mice) and db/db (1.209 ± 0.0158 µm, n=3
mice) mice [p=0.2466, unpaired t-test] (Figure 2.1E). These results demonstrate that AIS
shortening, but not AIS relocation, occurs in the medial prefrontal cortex of type 2
diabetic db/db mice.
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Development of signs of type 2 diabetes in db/db mice is associated with AIS shortening
in the prefrontal cortex
To determine if AIS shortening is associated with the development of type 2 diabetes in
db/db mice and persists over time, we analyzed metabolic signs of type 2 diabetes as
well as the AIS in control and db/db mice at three timepoints: beginning of diabetes (5
weeks of age), during fully developed diabetes (10 weeks of age) and after a prolonged
disease burden (26 weeks of age). We utilized male mice for these experiments to assess
potential sex differences as previously reported in db/db brain (Vannucci et al., 2001),
and because previous reports showed altered neurobehavioral outcomes in male db/db
mice at an early age (Specific Aim 1, (Li et al., 2002; Sharma et al., 2010; Dinel et al.,
2011)).
First, we measured blood glucose to confirm temporal development of type 2 diabetes.
At 5 weeks of age, there was no significant difference in blood glucose (Figure 2.2). At
10 weeks of age, db/db mice had profoundly elevated blood glucose (498.9 ± 60.8
mg/dL, n=4 mice) compared to controls (132.6 ± 5.8 mg/dL, n=4 mice) [p=0.0010,
unpaired t-test) (Figure 2.2). Similar to 10-week-old db/db mice, 26-week-old db/db
mice were also profoundly hyperglycemic (505.8 ± 60.8 mg/dL, n=4 mice) compared to
controls (131.3 ± 8.2 mg/dL, n=4 mice) [p<0.0001, unpaired t-test) (Figure 2.2).
We examined AIS structures by immunostaining brain sections as described above. A
potential confound of using db/db mice is that AIS shortening could be a byproduct of the
db/db genetic model, and not the development of diabetes, as they are leptin receptordeficient (Chen et al., 1996) and leptin signaling is involved in the neuronal and glial
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development of mouse embryos (Udagawa et al., 2006). However, at 5 weeks of age we
observed no difference in AIS length between control (28.58 ± 0.36 µm, n=4 mice) and
db/db (28.21 ± 0.65 µm, n=4 mice) mice [p=0.6280, unpaired t-test] (Figure 2.3A),
suggesting that lack of leptin signaling does not impact AIS formation in db/db mice
before overt signs of diabetes develop. At 10 weeks of age, AIS length was significantly
shorter in male db/db mice (22.25 ± 1.20 µm, n=4 mice) compared to controls (26.35 ±
0.97 µm, n=4 mice) [p=0.0376, unpaired t-test] (Figure 2.3A), consistent with AIS
shortening in 10-week-old female db/db mice (Figure 2.1C). To test if prolonged diabetic
state affects AIS shortening, we evaluated prefrontal cortex of 26-week-old db/db mice.
Similar to 10-week-old mice, AIS length was shorter in 26-week-old db/db mice (23.87 ±
0.70 μm, n = 4) compared with controls (26.87 ± 1.00 μm, n = 4) in prefrontal cortex
[p=0.0497, unpaired t-test] (Figure 2.3A). The cumulative frequency plot of individual
AIS lengths in prefrontal cortex of db/db mice showed a leftward shift in 10 and 26week-old db/db mice (Figure 2.3B).
AIS are shortened in the hippocampus of type 2 diabetic db/db mice
In addition to the cerebral cortex, previous studies indicate that the hippocampus is
involved in neuropsychiatric complications associated with type 2 diabetes in patients
(Gold et al., 2007) and in db/db mice (Li et al., 2002). Therefore, we also investigated
whether AIS was shortened in the hippocampus of the same animals used for prefrontal
cortex analyses. At 5 weeks of age, there was no difference in AIS length between
control (31.03 ± 1.145 µm, n=3 mice) and db/db (31.22 ± 0.12 µm, n=4 mice) mice
[p=0.8546, unpaired t-test] (Figure 2.4A). At 10 weeks, the AIS were significantly
shorter in db/db (27.56 ± 1.47 µm, n=4 mice) compared to control (32.81 ± 0.68 µm, n=4
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mice) mice [p=0.0184, unpaired t-test] (Figure 2.4A). AIS length was also shorter in
hippocampus of 26-week-old db/db mice (24.8 ± 0.68 μm, n = 4) compared with controls
(27.19 ± 0.57 μm, n = 3) [p=0.497, unpaired t-test] (Figure 2.4A), similar to the AIS in
medial prefrontal cortex (Figures 2.1, 2.3).
Nodal units in myelinated axons of type 2 diabetic db/db mice are preserved at 10 weeks
but not at 26 weeks of age
The nodal unit, consisting of a node of Ranvier, paranodes, and juxtaparanodes, is a
critical functional domain in myelinated axons that is needed for proper axonal
conduction and network communication. Importantly, the molecular organization at the
node of Ranvier is nearly identical to that at the AIS, including sodium channels, NF186,
ankyrinG, and βIV spectrin (Figure II, (Griggs et al., 2017; Nelson and Jenkins, 2017).
Furthermore, disruption of nodes of Ranvier has been reported in central nervous system
(CNS) diseases, such as schizophrenia (reviewed in (Roussos and Haroutunian, 2014)) or
lacunar stroke (Hinman et al., 2015), similar to AIS alterations in these same diseases.
Therefore, we examined if nodal units are affected in type 2 diabetic db/db mouse brain
at 10 and 26 weeks of age. We utilized the corpus callosum because it is a large bundle of
node of Ranvier-containing white matter fibers that connects the hemispheres of the brain
including the medial prefrontal cortex, and a previous study suggested that nodal
alterations in corpus callosum are closely associated with onset of major depressive
disorder (Miyata et al., 2016). We visualized the nodal unit using established markers of
nodes of Ranvier, paranodes, and juxtaparanodes. Immunostaining of nodal ankyrinG and
βIV spectrin appeared normal at 10 weeks (Figure 2.5A). We also examined clusters of
voltage-gated potassium channels (Kv1.2) at juxtaparanodes, since juxtaparanodal Kv1.2
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was reduced in peripheral nerves in db/db mice and in nerve biopsies from type 2 diabetic
patients (Zenker et al., 2012). The immunostaining of Kv1.2 channel clusters at
juxtaparanodes within the corpus callosum appeared similar in 10-week-old control and
db/db mice (Figure 2.5B). Next, we examined immunostaining of NF186 at nodes and
Caspr at paranodes, the region flanking both sides of the nodes in 10 and 26-week-old
mice (Figure 2.6A). The nodal gap, or the distance between two opposing Caspr clusters
within a single nodal unit, was similar in 10-week-old control and db/db mice (Figure
2.6B). However, the nodal gap was elongated in the corpus callosum of 26-week-old
db/db mice (1.181 ± 0.031 μm, n = 4) compared with controls (1.04 ± 0.023 μm, n = 4)
[p=0.0108, unpaired t-test] (Figure 2.6B). The length of a single paranodal Caspr cluster
was also similar in 10-week-old mice, but significantly reduced in 26-week-old db/db
mice (1.376 ± 0.042 μm, n = 4) compared with controls (1.578 ± 0.035 μm, n = 4)
[p=0.0099, unpaired t-test] (Figure 2.6C). This type of disruption at the nodes of Ranvier
in 26-week-old db/db mice suggests that the nodal elongation might be caused by partial
loss of the paranodal axo-glial junctions. Therefore, we show that nodal disruption occurs
in 26 but not 10-week-old mice, suggesting that prolonged course of type 2 diabetes is
likely necessary to disrupt this domain.
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Discussion
The current results are the first to show AIS shortening and nodes of Ranvier disruption
(elongation) associated with type 2 diabetes. Our data show AIS shortening occurs in
both medial prefrontal cortex and hippocampus in db/db mice at 10 and 26 weeks of age,
during a period when blood glucose levels are elevated. Despite striking similarity of
molecular composition and their function, nodes of Ranvier were not affected in 10week-old db/db mice, but disruption occurred later in the disease course, at 26 weeks of
age. Our findings may contribute to the understanding of mechanisms behind impaired
cognitive function and mood previously reported in db/db mice (Specific Aim 1, (Li et
al., 2002; Sharma et al., 2010; Dinel et al., 2011)) and patients with type 2 diabetes
(Stoeckel et al., 2016).
What is the functional consequence of AIS shortening in diabetic brain? The 8-16%
decrease in AIS length reported herein is likely functionally relevant—a computational
model showed that just a 4.5% decrease in AIS length reduces neuronal excitability
(Baalman et al., 2013). Similarly, shortening of AIS in hippocampal neuron culture by
25% was associated with dampened neuronal excitability (Evans et al., 2015). Thus, AIS
shortening due to diabetic conditions in db/db brains observed in this study might be a
primary disease pathology that likely results in decreased neuronal excitability, further
exacerbating the neuronal dysfunction caused by reduced dendritic spine density
(Stranahan et al., 2009; Chen et al., 2014a; Dhar et al., 2014). The idea of pathological
AIS shortening in diabetes is further supported by previous reports associating AIS
shortening with CNS pathology in rodent models of stroke (Hinman et al., 2013), mild
traumatic brain injury (Baalman et al., 2013; Vascak et al., 2017), Alzheimer’s disease

50

(Marin et al., 2016), or multiple sclerosis-related experimental autoimmune encephalitis
model (Clark et al., 2016b). Thus, our results strongly suggest that the modulation of
neuronal output by AIS shortening is involved in the pathophysiology of neuropsychiatric
complications during type 2 diabetes. Future studies could determine the contribution, if
any, of AIS shortening to cognitive and mood impairment in db/db mice.
In addition to AIS shortening, we observed elongation of nodes of Ranvier along the
corpus callosum in 26-week-old db/db mice, but not in 10-week-old mice (Figure 2.6),
suggesting that this disruption arises with prolonged diabetes burden. These nodal and
paranodal abnormalities might explain exacerbated deterioration of cognitive function in
older patients (Biessels et al., 2014), as well as in older db/db mice (Figure 1.5), since
nodal elongation can cause nerve conduction slowing (Babbs and Shi, 2013). Nodal
disruption might be indicative of white matter abnormalities as seen in patients with type
2 diabetes (Hsu et al., 2012), since node assembly and maintenance depends on
myelinating oligodendrocytes (Rasband and Peles, 2016; Griggs et al., 2017). Indeed, an
inverse relationship was observed between executive function and white matter integrity
in patients with type 2 diabetes (Manschot et al., 2006; Zhang et al., 2014). Furthermore,
adult-onset metabolic stress in oligodendrocytes causes progressive white matter
pathology, AIS shortening in entorhinal cortex, and memory deficits (Radecki et al.,
2018). Thus, our study highlights an important association of structural changes in
myelinated axons and cognitive dysfunction related to diabetes.
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Figure 2.1. Db/db mice have shortened AIS in medial prefrontal cortex
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Figure 2.1. (A) Representative images depicting the medial prefrontal cortex, prelimbic
area, in 10-week-old female control (left) and db/db (right) mice. Brain sections were
labeled for βIV spectrin (green, AIS), NeuN (red, neuronal soma) and Hoechst (blue, cell
nuclei). Scale bars = 20 µm.
(B) High magnification images of a single neuron and its AIS, labeled for βIV spectrin
(green, AIS), ankyrinG (red, AIS) and Hoechst (blue, cell nuclei). Brackets show AIS
length. Scale bars = 10 µm.
(C) AIS length in medial prefrontal cortex of 10-week-old female db/db mice was
shorter than controls (n=3 mice in each group).
(D) Cumulative frequency distribution plot of AIS lengths in medial prefrontal cortex
shows a leftward shift with no change in shape in db/db mice compared to controls.
Control, total 194 AISs from 3 mice; db/db, total 157 AISs from 3 mice.
(E) Distance from soma to AIS start point in medial prefrontal cortex of 10-week-old
female control and db/db mice was similar (n=3 mice in each group). ns = not
significant.
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Figure 2.2. Development and persistence of elevated blood glucose in db/db mice
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Figure 2.2. Blood glucose levels were similar in 5-week-old male control and db/db mice
(n=8). They were significantly elevated in both 10 (n=4) and 26-week-old mice (n=4).
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Figure 2.3. Diabetes-related AIS shortening in db/db mouse prefrontal cortex
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Figure 2.3. (A) AIS length in prefrontal cortex of 5-week-old control and db/db mice
was similar (n=4 mice in each group). AIS length in prefrontal cortex of 10-week-old
db/db mice was shorter than lean controls (n = 4 mice in each group). AIS length in
prefrontal cortex of 26-week-old db/db mice was shorter than lean controls (n = 4 mice
in each group).
(B) Cumulative frequency distribution plot of AIS lengths in prefrontal cortex shows
similar distribution in control and db/db mice at 5 weeks of age. Control, total 206 AIS
from 4 mice; db/db, total 193 AISs from 4 mice.
Cumulative frequency distribution plot of AIS lengths in prefrontal cortex shows a
leftward shift with no change in shape in db/db mice compared to controls at 10 weeks.
Control, total 249 AIS from 3 mice; db/db, total 203 AIS from 3 mice.
Cumulative frequency distribution plot of AIS lengths in prefrontal cortex shows a
leftward shift in db/db mice compared to controls at 26 weeks. Control total 251 AIS
from = 4 mice; db/db, total 254 AIS from 4 mice.
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Figure 2.4. Diabetes-related AIS shortening in db/db mouse hippocampus
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Figure 2.4. (A) AIS length in hippocampus of 5-week-old male control and db/db mice
was similar (n=3 mice in control group; n=4 in db/db group). AIS length in prefrontal
cortex of 10-week-old db/db mice was shorter than lean controls (n = 4 mice in each
group). AIS length in prefrontal cortex of 26-week-old db/db mice was shorter than lean
controls (n = 4 mice in each group).
(B) Cumulative frequency distribution plot of AIS lengths in hippocampus shows similar
distribution in control and db/db mice at 5 weeks of age. Control, total 45 AIS from 3
mice; db/db, total 59 AIS from 4 mice.
Cumulative frequency distribution plot of AIS lengths in hippocampus shows a leftward
shift in db/db mice compared to controls at 10 weeks. Control, total 59 AIS from 4 mice;
db/db, total 65 AIS from 4 mice.
Cumulative frequency distribution plot of AIS lengths in hippocampus shows a leftward
shift in db/db mice compared to controls at 26 weeks. Control total 120 AIS from 3
mice; db/db, total 147 AIS from 4 mice.
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Figure 2.5. Nodes of Ranvier are preserved in corpus callosum of 10-week-old db/db
mice
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Figure 2.5. (A) Representative high magnification images of nodal units in corpus
callosum of male control (left) and db/db (right) mice at 10 weeks of age. βIV spectrin
(βIVsp, green) labels the node and ankyrinG (AnkG, red) labels the node and paranodes.
Scale bars = 2 µm.
(B) Representative high magnification images of nodes and juxtaparanodes in corpus
callosum of male control (left) and db/db (right) mice at 10 weeks of age. Kv1.2 (blue)
labeling of the potassium channels at the juxtaparanode appeared similar in control and
db/db mice. Scale bars = 2 µm.
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Figure 2.6. Diabetes-related disruption of nodes of Ranvier at 26, but not at 10 weeks
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Figure 2.6. (A) Representative high magnification images of nodal units in corpus
callosum of male control and db/db mice at 10 (left) and 26 (right) weeks of age. Caspr
(green) labels paranodal junction and neurofascin (NF, red) labels the node. Brackets
represent the nodal gap. Scale bars = 2 µm.
(B) The nodal gap, or the distance between two opposing Caspr clusters within a single
nodal unit, was similar in control and db/db mice at 10 weeks of age (n=4). The nodal
gap was elongated in 26-week-old db/db mice (500 nodal gaps in each group of n = 4
mice).
(C) The length of a single paranodal Caspr cluster was similar in control and db/db mice
at 10 weeks of age (n=4). The length of a single paranodal Caspr cluster was shortened in
26-week-old db/db mice (1000 paranodes in each group of n = 4 mice).
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SPECIFIC AIM 3 –EXERCISE TREATMENT OF DB/DB MICE

The overall objective of this aim is to determine if exercise treatment prevents disruption
of AIS in db/db mice.

The results described in this chapter are published as “Yermakov LM, Drouet DE, Griggs
RB, Elased KM, Susuki K (2018) Type 2 diabetes leads to axon initial segment
shortening in db/db mice. Front Cell Neurosci 12:146. doi:10.3389/fncel.2018.00146.”

Introduction
In the previous chapter we have demonstrated that AIS length was significantly decreased
in the brains of 10-week-old db/db mice compared to age-matched controls, while no
difference was observed at 5 weeks of age (Figures 2.3, 2.4). This finding along with
development of overt hyperglycemia during the same time (Figure 2.2) suggests that type
2 diabetes causes AIS disruption. However, this is not conclusive. In addition, because of
the widespread distribution of leptin receptors in the brain (Leinninger and Myers, 2007),
there is a concern that AIS shortening might be a byproduct leptin-receptor mutation in
db/db mice (Chen et al., 1996).
Exercise has been considered a staple in diabetes management and prevention for decades
(Knowler et al., 2002; Sigal et al., 2006). In fact, it has been shown to be more effective
than the first-line anti-diabetic medication, metformin, for type 2 diabetes prevention in
nondiabetic persons with elevated fasting plasma glucose levels (Knowler et al., 2002). In
rodent models of type 2 diabetes, exercise has been shown to improve glucose tolerance
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and insulin resistance in mice given a high-fat diet (Boström et al., 2012) or leptin
receptor-deficient db/db mice (Somineni et al., 2014). Exercise has been utilized as a
preventive tool for delaying diabetic nephropathy (Somineni et al., 2014) and preserving
dendritic spines in the hippocampus of young db/db mice (Stranahan et al., 2009).
We hypothesized that exercise treatment would prevent or slow down the development of
type 2 diabetes in db/db mice which, in turn, would lead to amelioration of AIS
shortening in prefrontal cortex and hippocampus. Indeed, here we report that glucose and
HbA1c levels were improved and AIS shortening was not observed in db/db mice at the
end of exercise treatment. We suggest that development of type 2 diabetes is the cause of
AIS shortening in db/db mice, which likely plays an important role in disease
pathophysiology.
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Results
AIS shortening is not observed after exercise treatment
To determine if AIS shortening can be prevented or diminished by treatment of diabetes,
we analyzed AIS after anti-diabetic treatment (exercise) from 5 to 10 weeks of age, the
period during which elevated blood glucose developed (Figure 2.2).
To attenuate the progression of diabetes, control and db/db mice aged 5 weeks were
subjected to an exercise regimen using automated running wheel system (Somineni et al.,
2014). Exercise treatment in db/db mice reduced the temporal development of elevated
blood glucose [main effect of exercise in db/db mice; F(1,6) = 8.641, p=0.026]; two-way
ANOVA] (Figure 3.1A). There was no difference in HbA1c levels between male control
and db/db mice at the beginning of exercise, at 5 weeks of age (Figure 3.1B). As
expected based on previous studies (Hummel et al., 1966; Sharma et al., 2010), 5-weekold db/db mice were at the beginning of diabetes, since HbA1c reflects average blood
glucose concentration from approximately the previous 40 days—the average red blood
cell lifespan in mice (Wang et al., 2010). Without exercise, HbA1c levels were
significantly elevated in 10-week-old db/db mice (9.050 ± 0.786 %, n=4 mice)
compared to controls (5.850 ± 0.655 %, n=4 mice) [p=0.0427, two-way ANOVA
followed by Tukey’s] (Figure 3.1B). HbA1c levels in exercised db/db mice (6.175 ±
0.964 %, n=4 mice) were similar to that in exercised controls (4.625 ± 0.459 %, n=4
mice) [p=0.4767, two-way ANOVA followed by Tukey’s], confirming the effectiveness
of exercise treatment (Figure 3.1B). Neither age or exercise effected blood glucose or
HbA1c levels in control mice. After exercise treatment at 10 weeks of age, body weight
of the exercised db/db mice (42.875 ± 1.102 g, n=4 mice) was similar to that of non-
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exercised db/db mice (46.15 ± 1.341 g, n=4 mice) [p=0.1624, two-way ANOVA
followed by Tukey’s]. Together, these data demonstrate that exercise treatment
attenuated hyperglycemia, providing the appropriate experimental approach to test if
the development of type 2 diabetes changes AIS morphology.
Having demonstrated that AIS shortening develops between the ages of 5 to 10 weeks
(Figures 2.3, 2.4), we proceeded to test if AIS shortening is ameliorated by exercise
treatment starting at 5 weeks. Although the difference in AIS length in the medial
prefrontal cortex did not reach statistical significance at the end of exercise between the
exercising and non-exercising db/db mice [p=0.3124], AIS length in exercised db/db
mice (24.63 ± 0.73 µm, n=4 mice) was similar to that in exercised controls (25.25 ±
0.71 µm, n=4 mice) [p=0.9625, two-way ANOVA followed by Tukey’s] (Figure
3.2A,B). We also measured AIS in the hippocampus of control and db/db mice after
exercise treatment. Similar to the medial prefrontal cortex, no AIS shortening was
observed in hippocampus of db/db mice after exercise treatment: AIS length was
similar in exercised control (33.29 ± 1.15 µm, n=4 mice) and exercised db/db (31.01 ±
0.65 µm, n=4 mice) mice [p=0.4449, two-way ANOVA followed by Tukey’s] (Figure
3.3A,B). These results suggest that AIS shortening occurs during the period of
development of type 2 diabetes from 5 to 10 weeks of age, whereas AIS shortening does
not occur if hyperglycemia is controlled.
Finally, we performed a correlation analysis between AIS length and glucose or HbA1c
levels in db/db and control mice. There was an inverse correlation between AIS length in
the medial prefrontal cortex and blood glucose (r=-0.5327, p=0.0336, n=16) (Figure
3.2C) or HbA1c levels (r=-0.485, p=0.0569, n=16) (Figure 3.2D). Similarly, we found
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significant inverse correlation between AIS length and the levels of blood glucose (r=0.6567, p=0.0057, n=16) (Figure 3.3C) as well as HbA1c (r=-0.5155, p=0.0410, n=16)
(Figure 3.3D) in the hippocampus. These results further support our hypothesis that
development of type 2 diabetes leads to AIS shortening in both medial prefrontal cortex
and hippocampus, the brain regions that are implicated in development of cognitive
impairment and psychiatric symptoms in type 2 diabetic patients.
Neuronal, myelin, or AIS protein levels are unchanged in db/db mice
Progressive cortical atrophy has been reported in db/db mice starting at 14 weeks of age
(Infante-Garcia et al., 2017). To determine if reductions in neurons, myelin, or AIS
protein levels could explain AIS shortening in 10-week-old db/db mice, we examined
neuronal, myelin, and AIS markers in 10-week-old male control and db/db mice (both
without exercise) using immunostaining of the prefrontal cortex and western blotting of
frontal brain homogenates. The morphology in the prefrontal cortex appeared similar in
control and db/db mice (Figure 3.4A). The AIS density was similar between control (32 ±
1 AIS / field of view, n=4 mice) and db/db (33 ± 2 AIS / field of view, n=4 mice) mice
[p=0.6471, unpaired t-test]. Representative immunoblots are shown for NeuN, MBP, βIV
spectrin and the loading control protein GAPDH (Figure 3.4B). Consistent with
preserved cortical morphology (Figure 3.4A) and AIS density, there was no difference in
NeuN or MBP protein level (Figure 3.4C). The immunoblots showed lack of cleaved
caspase 3, a marker for apoptotic cell death, in both control and db/db brains (Figure
3.4D). Therefore, it is unlikely that the AIS shortening observed in 10-week-old db/db
mice is due to loss of neurons or myelinated axons. We also found no difference in the
protein level of βIV spectrin in the prefrontal cortex (Figure 3.4C). Similar to the medial
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prefrontal cortex (Figure 3.4A), NeuN-positive neurons and AIS immunostaining
appeared similar in the hippocampus CA1 area in male control and db/db mice without
exercise (Figure 3.5A). We also examined expression of neuron, myelin, and AIS
proteins in hippocampus in 10-week-old male control and db/db mice (both without
exercise). Consistent with preserved hippocampal morphology (Figure 3.5A), and similar
to the prefrontal cortex (Figure 3.4B,C), there were no differences in the protein levels of
NeuN, MBP, or βIV spectrin (Figure 3.5B,C), as well as cleaved caspase 3 (Figure 3.5D).
Together these findings suggest that in the AIS shortening we observed in prefrontal
cortex and hippocampi in 10-week-old diabetic animals is not secondary to gross changes
in neurons, myelination, or the AIS protein expression.
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Discussion
We report that AIS shortening was not observed after exercise treatment that improved
glycemic indices. In addition, AIS length was inversely correlated with signs of type 2
diabetes, such as hyperglycemia and elevated HbA1c. Together with our finding of
shortened AIS in 10 but not 5-week-old db/db mice, these observations convincingly
show that AIS shortening is caused by type 2 diabetes development.
Our results also demonstrated that while hyperglycemia in db/db mice was successfully
controlled via the exercise treatment (Figure 3.1), the weight of the diabetic animals was
not. This is consistent with previous studies that showed beneficial effects of exercise on
diabetes and its complications without body weight changes, including improved
glycemic control and albuminuria (Somineni et al., 2014), reduced allodynia (Cooper et
al., 2017), increased hippocampal dendritic spine density (Stranahan et al., 2009), and
prevention of type 2 diabetes in patients with impaired glucose tolerance (Pan et al.,
1997). This highlights the importance of exercise as a preventive anti-diabetic treatment,
despite its lack of effect on the animal’s weight.
We also show that AIS shortening occurred in the absence of changes in the
morphological appearance of neurons or in expression levels of neuronal and myelin
proteins. Therefore, it is unlikely that AIS shortening observed in 10-week-old db/db
mice is induced by neuronal loss (Ramos-Rodriguez et al., 2013) or disorganized myelin
(Nam et al., 2017) observed in rodent models at more advanced stages of type 2 diabetes.
Our results showing no difference in the expression levels of βIV spectrin, despite AIS
shortening, are consistent with a previous study in a mild traumatic brain injury model
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showing AIS shortening without changes in the levels of AIS proteins (Baalman et al.,
2013).
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Figure 3.1. Effect of exercise treatment on blood glucose and HbA1c levels
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Figure 3.1. (A) Blood glucose levels during daily exercise treatment. Exercise attenuated
the development of hyperglycemia in db/db mice (n=4 mice in each group). # p<0.05 for
control vs. db/db. * p<0.05 for db/db vs. db/db exercise.
(B) Left graph: HbA1c levels were similar before exercise in 5-week-old control and
db/db mice (n=8). Gray squares and circles represent mice binned to the exercise group.
Right graph: HbA1c levels at the end of exercise treatment in 10-week-old mice control
and db/db mice. Two-way ANOVA [diabetes x exercise: F(1,12) = 1.245; p=0.286]
followed by Tukey’s multiple comparisons test yielded the following p values: control vs
db/db [p=0.0427], control vs exercise control [p=0.6548], control vs exercise db/db
[p=0.9891], db/db vs exercise control [p=0.0055], db/db vs exercise db/db [p=0.0728],
exercise control vs exercise db/db [p=0.4767].
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Figure 3.2. Effect of exercise treatment on AIS length in db/db mouse prefrontal cortex
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Figure 3.2. (A) AIS length in medial prefrontal cortex of control and db/db mice with
and without exercise treatment (n=4 mice in each group). Two-way ANOVA [diabetes x
exercise: F(1,12) = 3.535; p=0.0846] followed by Tukey’s multiple comparisons test
yielded the following p values: control vs db/db [p=0.0374], control vs exercise control
[p=0.8338], control vs exercise db/db [p=0.5686], db/db vs exercise control [p=0.1537],
db/db vs exercise db/db [p=0.3124], exercise control vs exercise db/db [p=0.9625].
(B) Cumulative frequency distribution plots of AIS lengths in medial prefrontal cortex of
control and db/db mice. Control without exercise, total 255 AISs from 4 mice; db/db
mice without exercise, total 205 AISs from 4 mice; control with exercise, total 213 AISs
from 4 mice; db/db mice with exercise, total 239 AISs from 4 mice.
(C,D) Scatter plots of mean AIS lengths (y-axis) in relation to levels of blood glucose (C)
or HbA1c (D) (x-axis) of individual mouse at 10 weeks of age.
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Figure 3.3. Effect of exercise treatment on AIS length in db/db mouse hippocampus
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Figure 3.3. (A) AIS length in hippocampus of control and db/db mice with and without
exercise treatment (n=4 mice in each group). Two-way ANOVA [diabetes x exercise:
F(1,12) = 2.002; p=0.1825] followed by Tukey’s multiple comparisons test yielded the
following p values: control vs db/db [p=0.0184], control vs exercise control [p=0.9871],
control vs exercise db/db [p=0.6311], db/db vs exercise control [p=0.0103], db/db vs
exercise db/db [p=0.1454], exercise control vs exercise db/db [p=0.4449].
(B) Cumulative frequency distribution plots of AIS lengths in hippocampus of control
and db/db mice. Control without exercise, total 59 AISs from 4 mice; db/db mice without
exercise, total 65 AISs from 4 mice; control with exercise, total 48 AISs from 4 mice;
db/db mice with exercise, total 61 AISs from 4 mice.
(C,D) Scatter plots of mean AIS length (y-axis) in relation to levels of blood glucose (C)
or HbA1c (D) (x-axis) of individual mouse at 10 weeks of age.
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Figure 3.4. No major changes of protein levels in neurons, myelin, and AIS in 10-weekold db/db mouse prefrontal cortex
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Figure 3.4. (A) Representative images depicting the medial prefrontal cortex, prelimbic
area, in 10-week-old male control (left) and db/db (right) mice. Brain sections were
labeled for βIV spectrin (green, AIS), NeuN (red, neuronal soma) and Hoechst (blue, cell
nuclei). Scale bars = 20 µm.
(B) Representative immunoblots of homogenized frontal brain from control and db/db
mice at 10 weeks of age. βIVsp = βIV spectrin. Uncropped images of the entire original
immunoblots are shown in Appendix.
(C) Quantification of relative protein band densities, normalized to GAPDH, and
reported in arbitrary units (AU). No difference in protein levels was evident between
control and db/db mice (n=3). Student’s t-tests yielded the following p values: NeuN
[p=0.9824], both MBP upper and lower bands [p=0.0652], βIV spectrin lower band,
βIVƩ6 spectrin, a major isoform in adult brain (Yoshimura et al., 2016) [p=0.2884].
(D) Representative immunoblots of homogenized frontal lobes from control and db/db
mice at 10 weeks of age. PC = Positive Control, which consisted of Jurkat cells +
Cytochrome c (Cell Signaling Technology Cat#9663) and served as positive control for
antibody. Uncropped images of the entire original immunoblots are shown in Appendix.
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Figure 3.5. No major changes of protein levels in neurons, myelin, and AIS in 10-weekold db/db mouse hippocampus
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Figure 3.5. (A) Representative images depicting hippocampus, CA1 area, in 10-week-old
male control (left) and db/db (right) mice (both without exercise treatment). Brain
sections were labeled for βIV spectrin (green, AIS), NeuN (red, neuronal soma) and
Hoechst (blue, cell nuclei). Scale bars = 10 µm.
(B) Representative immunoblots of homogenized hippocampus from control and db/db
mice at 10 weeks of age (both with no exercise). βIVsp = βIV spectrin. Uncropped
images of the entire original immunoblots are shown in Appendix.
(C) Quantification of relative protein band densities, normalized to GAPDH, and
reported in arbitrary units (AU). No difference in protein levels was evident between
control and db/db mice (n=3). Student’s t-tests yielded the following p values: NeuN
[p=0.3401], both MBP upper and lower bands [p=0.9782], βIV spectrin lower band,
βIVƩ6 spectrin, a major isoform in adult brain (Yoshimura et al., 2016) [p=0.4822].
(D) Representative immunoblots of homogenized hippocampus from control and db/db
mice at 10 weeks of age. PC = Positive Control, which consisted of Jurkat cells +
Cytochrome c (Cell Signaling Technology Cat#9663) and served as positive control for
antibody. Uncropped images of the entire original immunoblots are shown in Appendix.
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CONCLUSION AND FUTURE DIRECTIONS

For the first time, we report significant impairment of cognitive flexibility in type 2
diabetic db/db mice. Along with working memory, cognitive flexibility is the key
executive function for diabetes management and quality of life in patients (Feil et al.,
2012; Black et al., 2018). In addition to previous reports of impaired learning and
memory (Biessels et al., 1996; Li et al., 2002; Stranahan et al., 2008; Chen et al., 2014a;
Infante-Garcia et al., 2017; Zheng et al., 2017) and depression-like behavior (Li et al.,
2002; Sharma et al., 2010, 2012), our finding of impaired cognitive flexibility (Specific
Aim 1) establishes db/db mice as a model that closely parallels cognitive and mood
deficits in patients with type 2 diabetes.
The pathophysiology underlying cognitive and mood dysfunction in type 2 diabetes is
unknown. Studies in patients with type 2 diabetes describe neuroanatomical
abnormalities in hippocampus (Gold et al., 2007) and prefrontal cortex (Kumar et al.,
2008), implicating these regions. Previous studies suggest that type 2 diabetes alters
synaptic plasticity in the hippocampus resulting in cognitive deficits in db/db mice (Li et
al., 2002; Stranahan et al., 2008). In addition, db/db mice have reduced dendritic spine
density in dentate gyrus granule neurons in the hippocampus (Stranahan et al., 2009),
hippocampal CA1 (Chen et al., 2014a) and CA3 pyramidal neurons (Dhar et al., 2014),
and layer II/III pyramidal neurons in prefrontal cortex (Chen et al., 2014a). Our current
results (Specific Aim 2) demonstrate shortening of the AIS in hippocampal CA1 and
layer II/III neurons in prefrontal cortex, as well as elongation of nodes of Ranvier along
the corpus callosum. Similar to the effects of exercise treatment in the current study
(Specific Aim 3), voluntary running wheel activity attenuated reduction of dendritic spine
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density in hippocampus in db/db mice (Stranahan et al., 2009). Thus, these structural
changes in AIS and nodes of Ranvier together with synaptic loss likely disturb the
neuronal network coordination presumably required for appropriate cognitive function in
type 2 diabetic db/db mice.
The summary of our major findings along with key diabetes-associated events, such as
the onset of insulin resistance and cortical atrophy in db/db mice, are presented in Figure
4.1.
There are many questions that remain to be answered. For example, one important
question is whether the lack of functional leptin receptor in db/db mice may contribute to
AIS shortening, nodal elongation and cognitive impairment. Leptin signaling plays an
important role in neuronal and glial development of mouse embryos (Udagawa et al.,
2006). Our data suggests that the AIS shortening in db/db mice was not due to disrupted
leptin signaling, since diabetes treatment ameliorated AIS shortening (Specific Aim 3).
Moreover, a study using leptin-deficient ob/ob mice, an established model of obesity but
only mild and transient hyperglycemia (Wang et al., 2014a; Giesbertz et al., 2015),
showed preserved cognitive flexibility in MWM reversal, as well as preserved dendritic
spine density in the hippocampus at 16-24 week of age (Bracke et al., 2019). This further
supports the hypothesis that type 2 diabetes condition and not obesity or disturbed leptin
signaling is what leads to neurobehavioral deficits and morphological brain changes in
db/db mice. Analyses of other models of type 2 diabetes, such as high-fat diet commonly
used to induce insulin resistance in rodents (Buettner et al., 2006), may be used to address
this issue further.
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What is the relationship among alterations in synapses, AIS, nodes, and myelin that
culminate in cognitive dysfunction in type 2 diabetes? Our results cannot distinguish
between AIS shortening as the result of neuronal homeostatic plasticity or as a type 2
diabetes pathology or both. Presumably, reduced dendritic spines would lead to decreased
input and compensatory AIS lengthening and/or relocation. However, both AIS
shortening (Specific Aim 2) and reduced dendritic spine density (Stranahan et al., 2009;
Chen et al., 2014a; Dhar et al., 2014) are reported in similarly aged db/db mice displaying
cognitive and mood dysfunction (Specific Aim 1, (Li et al., 2002; Sharma et al., 2010)).
This suggests that AIS shortening is a pathological change caused by type 2 diabetes,
rather than adaptive or compensatory change to maintain neural circuit activities.
However, one also needs to consider a scenario in which both AIS shortening and
reduction in dendritic spine density could be compensatory to yet another pathological
mechanism causing overall network hyperexcitability, as has been recently reported in
the case of GABAergic synapse loss at the AIS (Nelson et al., 2018). Similarly, we do not
know if the node of Ranvier elongation along corpus callosum in db/db mice at 26 weeks
is due to diabetes or secondary to brain damage, such as myelin defects, or both. Future
studies need to test if long-term diabetes treatment (5-26 weeks) with exercise or
established anti-diabetic drug such as rosiglitazone can ameliorate the nodal disruption.
Detailed information on AIS changes in neuronal subtypes (e.g. excitatory vs. inhibitory)
is necessary for a comprehensive understanding of disturbed neural circuits under
diabetic conditions. Even though it is likely that AIS shortening occurs to a similar
degree in all populations of neurons (Figure 2.1D), this is not conclusive, because
detailed information for cell-type-specific AIS shortening is lacking. Previous studies
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show that neuronal cell-type is important in either diabetic brain complications or AIS
morphology. Loss or changes of specific types of inhibitory neurons have been reported
in type 2 diabetic Goto-Kakizaki rats (Larsson et al., 2016). AIS length is substantially
heterogeneous in interneurons and pyramidal neurons (Höfflin et al., 2017), and the
pattern of activity-dependent AIS changes is different between inhibitory interneurons
and excitatory neurons (Chand et al., 2015). Cell-type-specific analyses of AIS changes
could be an important next step to better understand pathophysiology of diabetic brain
complications.
In addition, what are the molecular and cellular mechanisms of excitable axonal domain
disruption in diabetic brain? Some researchers propose that type 2 diabetes and
Alzheimer’s disease might share metabolic dysfunction upstream of the observed
cognitive decline (Chornenkyy et al., 2018). Such dysfunction likely begins early in the
disease process and might explain cognitive decrements observed among type 2 diabetes
patients of all ages (Biessels et al., 2014). Interestingly, type 2 diabetes is clinically
associated with both Alzheimer’s disease-type and vascular-type dementias (Chornenkyy
et al., 2018), and AIS shortening has been reported in mouse models of both Alzheimer’s
disease (Marin et al., 2016) and cerebrovascular lesions (Hinman et al., 2013; Coban et
al., 2017). Potential metabolic disruptors of axonal domains might include mitochondrial
dysfunction (Neth and Craft, 2017) or increased glucose metabolite methylglyoxal
(Bierhaus et al., 2012), which have been shown to disrupt nodes of Ranvier (Marella et
al., 2013; Griggs et al., 2018) and oxidative stress (Verma et al., 2016), which induces
AIS disruption (Clark et al., 2017).
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Previous studies also indicate that both homeostatic plasticity and pathological alterations
of the AIS involve changes in intracellular calcium (Ca2+) levels and calcium-dependent
enzymes. Pathological AIS alterations are mediated by calpain, a calcium-dependent
cysteine protease, in models of stroke (Schafer et al., 2009), induced excitotoxicity (del
Puerto et al., 2015; Benned-Jensen et al., 2016), and multiple sclerosis (Clark et al.,
2016b). In addition, hyperphosphorylated tau (Hatch et al., 2017) or oxidative stress
followed by calpain activation (Clark et al., 2017) induce pathological alterations of AIS.
Calcium/calmodulin-dependent kinase II (CaMKII) may regulate excitability through its
interaction with ankyrinG and βIV spectrin complex that anchor it to the AIS (Hund et
al., 2010). Interestingly, a study looking at proteomic profile in db/db mice found altered
expression of CaMKIIα, CaMKIIβ, CaMKIIδ and calcineurin subunit B type 1 both in
hippocampus and frontal cortex (Ernst et al., 2013), and post-translational OGlcNAcylation of CaMKII is increased in the diabetic brain (Erickson et al., 2013).
Calcineurin, a calcium/calmodulin-dependent protein phosphatase, is responsible for both
activity-dependent relocation (Evans et al., 2013) and shortening (Evans et al., 2015) of
the AIS. Furthermore, AIS assembly, maintenance, and/or plasticity may also be
regulated by cannabinoid receptors (Tapia et al., 2017), brain-derived neurotrophic factor
and neurotrophin 3 (Guo et al., 2017), protein kinase CK2 (Bréchet et al., 2008; Hien et
al., 2014; Xu and Cooper, 2015; Lezmy et al., 2017), Cdk5 (Trunova et al., 2011; Chand
et al., 2015), microtubule cross-linking factor 1 (Satake et al., 2017), myosin II activity
(Evans et al., 2017; Berger et al., 2018), or Rbfox splicing factors (Jacko et al., 2018).
Future studies are required to identify the key mechanism of diabetes-related AIS
changes. Induction of diabetes in the mutant mice with disruption of these mediators
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would be a powerful approach to uncover the key regulator of structural changes in AIS
and nodes of Ranvier during diabetic brain complications.
Finally, while our current results demonstrate that excitable axonal domains are affected
in association with the development of type 2 diabetes, are the excitable axonal domains
modulated in the setting of type 1 diabetes? Similar to type 2 diabetes discussed above,
learning and memory deficits are also reported in patients with early-onset type 1
diabetes (Semenkovich et al., 2016a, 2016b). The streptozotocin model of type 1 diabetes
is associated with depression (Castillo-Gómez et al., 2015), learning and memory
impairment (Biessels et al., 1996; Stranahan et al., 2008), reduced long term potentiation
in the prefrontal cortex (Wu et al., 2017), and reduced dendritic spine density in
hippocampus (Wang et al., 2014b; Xiang et al., 2015) and prefrontal cortex (Wu et al.,
2017). Analyses of human brain tissues are also required to confirm the roles of disrupted
excitable axonal domains in the pathophysiology of type 1 as well as type 2 diabetes.
In conclusion, this is the first study to report impairment of cognitive flexibility in type 2
diabetic db/db mice. In addition, we report structural changes at the AIS and nodes of
Ranvier associated with the development of type 2 diabetes. We report AIS shortening in
medial prefrontal cortex and hippocampus, and nodes of Ranvier disruption along the
corpus callosum, the brain regions critical for appropriate cognitive function and affect.
In addition to the dendritic plasticity modulating neuronal inputs, the disruption of
excitable axonal domains regulating neuronal outputs might contribute to the
development of neuropsychiatric symptoms during type 2 diabetes. Thus, treatments
aiming to restore these domains might be a novel strategy to ameliorate cognitive and
mood impairments in type 2 diabetes.
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Figure 4.1. Timeline of major diabetes-associated events in db/db mice
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Figure 4.1. Db/db (BKS.Cg-Dock7m +/+ Leprdb/J) mice (Hummel et al., 1966) start to
develop insulin resistance around 10-14 days. Obesity starts at 3-4 weeks of age.
Hyperglycemia onset is between 4 to 8 weeks. We (Specific Aim 1) and others (Li et al.,
2002; Sharma et al., 2010) report cognitive impairment at around 7-10 weeks of age.
Progressive cortical atrophy has been reported starting at 14 weeks of age (Infante-Garcia
et al., 2017). We found preserved excitable axonal domains at 5 weeks, AIS shortening at
10 and 26 weeks of age and nodal elongation at 26 weeks of age (Specific Aim 2). Db/db
mice die prematurely at around 10 months of age.
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APPENDIX

Supplementary Figure S1. Original immunoblots for Figure 3.4B.
Original full-size immunoblots of homogenized frontal brains, stained with antibody to
NeuN (A), MBP (B), βIV spectrin (C), and GAPDH (D).
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Supplementary Figure S2. Original immunoblots for Figure 3.4D.
(A-C) Original full-size immunoblot of homogenized frontal lobes, stained with antibody
to cleaved caspase 3, with short exposure time (A) or long exposure time (B); and stained
with antibody to GAPDH (C). Untreated Jurkat (negative control) and Jurkat cells +
Cytochrome c (positive control) were used as controls (Cell Signaling Technology
Cat#9663).
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Supplementary Figure S3. Original immunoblots for Figure 3.5B.
Original full-size immunoblots of homogenized hippocampi, stained with antibody to
NeuN (A), MBP (B), βIV spectrin (C), and GAPDH (D).
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Supplementary Figure S4. Original immunoblots for Figure 3.5D.
(A-C) Original full-size immunoblot of homogenized hippocampi, stained with antibody
to cleaved caspase 3, with short exposure time (A) or long exposure time (B); and stained
with antibody to GAPDH (C). Untreated Jurkat (negative control) and Jurkat cells +
Cytochrome c (positive control) were used as controls (Cell Signaling Technology
Cat#9663).
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